In a previous study from our group, we reported that the Mel-18 gene functioned as a tumor suppressor in prostate cancer, and a SNP (1805A/G) in the miRNA-181a binding site correlated with Mel-18 expression and clinical features in prostate cancer [18]. The gene discussed is PCGF2; the disease is prostate cancer.